The expression of Claudin 1 correlates with β-catenin and is a prognostic factor of poor outcome in gastric cancer

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1293-1301

  Huang, Jie ^a   Li, Jianfang ^a   Qu, Ying ^b   Zhang, Jianian ^a   Zhang, Li ^a   Chen, Xuehua ^b   Liu, Bingya ^a   Zhu, Zhenggang ^a  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

catenin; Claudin 1; Gastric cancer

Indexed keywords

BETA CATENIN; CLAUDIN 1; CLDN1 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR MARKER;

AGED; BIOSYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; MORTALITY; RNA INTERFERENCE; STOMACH TUMOR; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; BETA CATENIN; CELL LINE, TUMOR; CLAUDIN-1; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84894429410     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2298     Document Type: Article

References (43)

1. Brenner H, Rothenbacher D and Arndt V: Epidemiology of stomach cancer. Methods Mol Biol 472: 467-477, 2009.
2. Du C, Zhou Y, Cai H, Zhao G, Fu H and Shi YQ: Poor prognostic factors in patients with stage I gastric cancer according to the seventh edition TNM classification: a comparative analysis of three subgroups. J Surg Oncol 105: 323-328, 2012.
3. Lazar D, Taban S, Sporea I, et al: Gastric cancer: correlation between clinicopathological factors and survival of patients (III). Rom J Morphol Embryol 50: 369-379, 2009.
4. Lazar D, Taban S, Sporea I, et al: Gastric cancer: correlation between clinicopathological factors and survival of patients. II. Rom J Morphol Embryol 50: 185-194, 2009.
5. Tsukita S and Furuse M: Claudin-based barrier in simple and stratified cellular sheets. Curr Opin Cell Biol 14: 531-536, 2002. (Pubitemid 35251880)
6. Tobioka H, Isomura H, Kokai Y, Tokunaga Y, Yamaguchi J and Sawada N: Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol 35: 159-164, 2004. (Pubitemid 38240897)
7. Pope JL, Bhat AA, Sharma A, et al: Claudin-1 regulates intestinal epithelial homeostasis through the modulation of Notch-signalling. Gut: Jun 13, 2013 (Epub ahead of print).
8. Noda S, Tanabe S and Suzuki T: Naringenin enhances intestinal barrier function through the expression and cytoskeletal association of tight junction proteins in Caco-2 cells. Mol Nutr Food Res 57: 2019-2028, 2013.
9. Iraha A, Chinen H, Hokama A, et al: Fucoidan enhances intestinal barrier function by upregulating the expression of claudin-1. World J Gastroenterol 19: 5500-5507, 2013.
10. Myal Y, Leygue E and Blanchard AA: Claudin 1 in breast tumorigenesis: revelation of a possible novel 'claudin high' subset of breast cancers. J Biomed Biotechnol 2010: 956897, 2010.
11. Blanchard AA, Ma X, Dueck KJ, et al: Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 13: 268, 2013.
12. Chang TL, Ito K, Ko TK, et al: Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology 138: 255-265, 2010.
13. Qin W, Ren Q, Liu T, Huang Y and Wang J: MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett 587: 1434-1439, 2013.
14. Chao YC, Pan SH, Yang SC, et al: Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179: 123-133, 2009.
15. Dhawan P, Singh AB, Deane NG, et al: Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115: 1765-1776, 2005. (Pubitemid 40979715)
16. Kinugasa T, Akagi Y, Ochi T, et al: Increased claudin-1 protein expression in hepatic metastatic lesions of colorectal cancer. Anticancer Res 32: 2309-2314, 2012.
17. Ersoz S, Mungan S, Cobanoglu U, Turgutalp H and Ozoran Y: Prognostic importance of Claudin-1 and Claudin-4 expression in colon carcinomas. Pathol Res Pract 207: 285-289, 2011.
18. Morohashi S, Kusumi T, Sato F, et al: Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20: 139-143, 2007.
19. Zhang Z, Wang A, Sun B, Zhan Z, Chen K and Wang C: Expression of CLDN1 and CLDN10 in lung adenocarcinoma in situ and invasive lepidic predominant adenocarcinoma. J Cardiothorac Surg 8: 95, 2013.
20. Matsuda Y, Semba S, Ueda J, et al: Gastric and intestinal claudin expression at the invasive front of gastric carcinoma. Cancer Sci 98: 1014-1019, 2007. (Pubitemid 46865385)
21. Suh Y, Yoon CH, Kim RK, et al: Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells. Oncogene 32: 4873-4882, 2013.
22. Singh AB, Sharma A and Dhawan P: Claudin-1 expression confers resistance to anoikis in colon cancer cells in a Src-dependent manner. Carcinogenesis 33: 2538-2547, 2012.
23. Singh AB, Sharma A, Smith JJ, et al: Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 141: 2140-2153, 2011.
24. Shiozaki A, Bai XH, Shen-Tu G, et al: Claudin 1 mediates TNFalpha-induced gene expression and cell migration in human lung carcinoma cells. PLoS One 7: e38049, 2012.
25. Di Cello F, Cope L, Li H, et al: Methylation of the claudin 1 promoter is associated with loss of expression in estrogen receptor positive breast cancer. PLoS One 8: e68630, 2013.
26. Blanchard AA, Skliris GP, Watson PH, et al: Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 454: 647-656, 2009.
27. Moldvay J, Jackel M, Paska C, Soltesz I, Schaff Z and Kiss A: Distinct claudin expression profile in histologic subtypes of lung cancer. Lung Cancer 57: 159-167, 2007. (Pubitemid 47043180)
28. Miwa N, Furuse M, Tsukita S, Niikawa N, Nakamura Y and Furukawa Y: Involvement of claudin-1 in the beta-catenin/Tcf signaling pathway and its frequent upregulation in human colorectal cancers. Oncol Res 12: 469-476, 2001. (Pubitemid 33791807)
29. Bhat AA, Sharma A, Pope J, et al: Caudal homeobox protein Cdx-2 cooperates with Wnt pathway to regulate claudin-1 expression in colon cancer cells. PLoS One 7: e37174, 2012.
30. Shiou SR, Singh AB, Moorthy K, et al : Smad4 regulates claudin-1 expression in a transforming growth factor-beta-independent manner in colon cancer cells. Cancer Res 67: 1571-1579, 2007. (Pubitemid 46383381)
31. Sharma A, Bhat AA, Krishnan M, Singh AB and Dhawan P: Trichostatin-A modulates claudin-1 mRNA stability through the modulation of Hu antigen R and tristetraprolin in colon cancer cells. Carcinogenesis 34: 2610-2621, 2013.
32. Krishnan M, Singh AB, Smith JJ, et al: HDAC inhibitors regulate claudin-1 expression in colon cancer cells through modulation of mRNA stability. Oncogene 29: 305-312, 2010.
33. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ and Levin B: bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 55: 237-241, 1995.
34. Mrsny RJ, Brown GT, Gerner-Smidt K, et al: A key claudin extracellular loop domain is critical for epithelial barrier integrity. Am J Pathol 172: 905-915, 2008. (Pubitemid 351519988)
35. Stebbing J, Filipovic A and Giamas G: Claudin-1 as a promoter of EMT in hepatocellular carcinoma. Oncogene 32: 4871-4872, 2013.
36. Yoon CH, Kim MJ, Park MJ, et al: Claudin-1 acts through c-Abl-protein kinase Cdelta (PKCdelta) signaling and has a causal role in the acquisition of invasive capacity in human liver cells. J Biol Chem 285: 226-233, 2010.
37. Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, Fortoul TI, Montano LF and Rendon-Huerta EP: Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Invest 29: 1-11, 2011.
38. Soini Y, Tommola S, Helin H and Martikainen P: Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch 448: 52-58, 2006. (Pubitemid 43177415)
39. Resnick MB, Gavilanez M, Newton E, et al: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol 36: 886-892, 2005. (Pubitemid 41187907)
40. Wu YL, Zhang S, Wang GR and Chen YP: Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol 14: 4943-4948, 2008.
41. Demir R, Dimmler A, Naschberger E, et al: Malignant progression of invasive tumour cells seen in hypoxia present an accumulation of beta-catenin in the nucleus at the tumour front. Exp Mol Pathol 87: 109-116, 2009.
42. Li YP, Wu CC, Chen WT, Huang YC and Chai CY: The expression and significance of WWOX and beta-catenin in hepatocellular carcinoma. APMIS 121: 120-126, 2013.
43. Ooi CH, Ivanova T, Wu J, et al: Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet 5: e1000676, 2009.